The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 37447-37457

  Epstein, Linda F ^a   Chen, Hao ^a   Emkey, Renee ^a   Whittington, Douglas A ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION LOOPS; ANAPLASTIC LYMPHOMA KINASE; NEUROBLASTOMAS;

ONCOLOGY;

ENZYMES;

ADENOSINE TRIPHOSPHATE; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA PROTEIN COMPLEX; DRUG BINDING SITE; DRUG DESIGN; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; NEUROBLASTOMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; AMINO ACID MOTIFS; ANIMALS; BENZOXAZOLES; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MUTATION, MISSENSE; NEUROBLASTOMA; PROTEIN BINDING; PROTEOLYSIS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SPODOPTERA; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84868236578     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.391425     Document Type: Article

References (64)

1. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., and Look, A. T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284
2. Kuefer, M. U., Look, A. T., Pulford, K., Behm, F. G., Pattengale, P. K., Mason, D. Y., and Morris, S. W. (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90, 2901-2910
3. Bischof, D., Pulford, K., Mason, D. Y., and Morris, S. W. (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell Biol. 17, 2312-2325
4. Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., and Yamamoto, T. (1996) Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl. Acad. Sci. U.S.A. 93, 4181-4186
5. Lange, K., Uckert, W., Blankenstein, T., Nadrowitz, R., Bittner, C., Renauld, J. C., van Snick, J., Feller, A. C., and Merz, H. (2003) Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22, 517-527
6. Grande, E., Bolós, M. V., and Arriola, E. (2011) Targeting oncogenic ALK. A promising strategy for cancer treatment. Mol. Cancer Ther. 10, 569-579
7. Griffin, C. A., Hawkins, A. L., Dvorak, C., Henkle, C., Ellingham, T., and Perlman, E. J. (1999) Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776-2780
8. Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D., and Fletcher, J. A. (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377-384
9. Arber, D. A., Sun, L. H., and Weiss, L. M. (1996) Detection of the t(2; 5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum. Pathol. 27, 590-594
10. Laurent, C., Do, C., Gascoyne, R. D., Lamant, L., Ysebaert, L., Laurent, G., Delsol, G., and Brousset, P. (2009) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma. A rare clinicopathologic entity with poor prognosis. J. Clin. Oncol. 27, 4211-4216
11. Jazii, F. R., Najafi, Z., Malekzadeh, R., Conrads, T. P., Ziaee, A. A., Abnet, C., Yazdznbod, M., Karkhane, A. A., and Salekdeh, G. H. (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of α-tropomyosin expression in esophageal cancer. World J. Gastroenterol. 12, 7104-7112
12. Du, X. L., Hu, H., Lin, D. C., Xia, S. H., Shen, X. M., Zhang, Y., Luo, M. L., Feng, Y. B., Cai, Y., Xu, X., Han, Y. L., Zhan, Q. M., and Wang, M. R. (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 85, 863-875
13. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., and Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448, 561-566
14. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., Macneill, J., Ren, J. M., Yuan, J., Bakalarski, C. E., Villen, J., Kornhauser, J. M., Smith, B., Li, D., Zhou, X., Gygi, S. P., Gu, T. L., Polakiewicz, R. D., Rush, J., and Comb, M. J. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203
15. Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Ding, P., Liu, Y., Sun, F., Schultz, P. G., Gray, N. S., and Warmuth, M. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. U.S.A. 104, 270-275
16. Sabbatini, P., Korenchuk, S., Rowand, J. L., Groy, A., Liu, Q., Leperi, D., Atkins, C., Dumble, M., Yang, J., Anderson, K., Kruger, R. G., Gontarek, R. R., Maksimchuk, K. R., Suravajjala, S., Lapierre, R. R., Shotwell, J. B., Wilson, J. W., Chamberlain, S. D., Rabindran, S. K., and Kumar, R. (2009) GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 8, 2811-2820
17. Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., and Los, G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322
18. Cheng, M., Quail, M. R., Gingrich, D. E., Ott, G. R., Lu, L., Wan, W., Albom, M. S., Angeles, T. S., Aimone, L. D., Cristofani, F., Machiorlatti, R., Abele, C., Ator, M. A., Dorsey, B. D., Inghirami, G., and Ruggeri, B. A. (2012) CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 11, 670-679
19. Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P. P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., McTigue, M., Grodsky, N., Ryan, K., Padrique, E., Alton, G., Timofeevski, S., Yamazaki, S., Li, Q., Zou, H., Christensen, J., Mroczkowski, B., Bender, S., Kania, R. S., and Edwards, M. P. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363
20. Ott, G. R., Tripathy, R., Cheng, M., McHugh, R., Anzalone, A. V., Underiner, T. L., Curry, M. A., Quail, M. R., Lu, L., Wan, W., Angeles, T. S., Albom, M. S., Aimone, L. D., Ator, M. A., Ruggeri, B. A., and Dorsey, B. D. (2010) Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med. Chem. Lett. 1, 493-498
21. Kinoshita, K., Kobayashi, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Hattori, K., Miyagi, T., Hong, W. S., Park, M. J., Takanashi, K., Tsukaguchi, T., Sakamoto, H., Tsukuda, T., and Oikawa, N. (2011) 9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b- ]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J. Med. Chem. 54, 6286-6294
22. Ott, G. R., Wells, G. J., Thieu, T. V., Quail, M. R., Lisko, J. G., Mesaros, E. F., Gingrich, D. E., Ghose, A. K., Wan, W., Lu, L., Cheng, M., Albom, M. S., Angeles, T. S., Huang, Z., Aimone, L. D., Ator, M. A., Ruggeri, B. A., and Dorsey, B. D. (2011) 2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines. New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J. Med. Chem. 54, 6328-6341
23. Palmer, R. H., Vernersson, E., Grabbe, C., and Hallberg, B. (2009) Anaplastic lymphoma kinase. Signalling in development and disease. Biochem. J. 420, 345-361
24. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., and Yamamoto, T. (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449
25. Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., and Witte, D. P. (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene 14, 2175-2188
26. Vernersson, E., Khoo, N. K., Henriksson, M. L., Roos, G., Palmer, R. H., and Hallberg, B. (2006) Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448-461
27. Pulford, K., Lamant, L., Morris, S. W., Butler, L. H., Wood, K. M., Stroud, D., Delsol, G., and Mason, D. Y. (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394-1404
28. Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N. J., Brodeur, G. M., Tonini, G. P., Rappaport, E., Devoto, M., and Maris, J. M. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935
29. Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., Valteau-Couanet, D., Frebourg, T., Michon, J., Lyonnet, S., Amiel, J., and Delattre, O. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970
30. Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., Nakagawara, A., Hayashi, Y., Mano, H., and Ogawa, S. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974
31. George, R. E., Sanda, T., Hanna, M., Fröhling, S., Luther, W., 2nd, Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., Xue, L., Zozulya, S., Gregor, V. E., Webb, T. R., Gray, N. S., Gilliland, D. G., Diller, L., Greulich, H., Morris, S. W., Meyerson, M., and Look, A. T. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978
32. 1275 impairs receptor trafficking. Oncogene 30, 2017-2025
33. Schönherr, C., Ruuth, K., Yamazaki, Y., Eriksson, T., Christensen, J., Palmer, R. H., and Hallberg, B. (2011) Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem. J. 440, 405-413
34. Janoueix-Lerosey, I., Schleiermacher, G., and Delattre, O. (2010) Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29, 1566-1579
35. Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., Christensen, J. G., Maris, J. M., Lemmon, M. A., and Mosse, Y. P. (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114
36. Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., Shapiro, G. I., Rodig, S. J., Eck, M. J., and Jänne, P. A. (2010) The neuroblastoma- associated F1174LALKmutation causes resistance to anALKkinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038-10043
37. Camidge, D. R., and Doebele, R. C. (2012) Treating ALK-positive lung cancer. Early successes and future challenges. Nat. Rev. Clin. Oncol. 9, 268-277
38. Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., Gao, M. Y., Hua, S., Chen, C., Kim, S., Michellys, P. Y., Lesley, S. A., Harris, J. L., and Spraggon, G. (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J. 430, 425-437
39. Bossi, R. T., Saccardo, M. B., Ardini, E., Menichincheri, M., Rusconi, L., Magnaghi, P., Orsini, P., Avanzi, N., Borgia, A. L., Nesi, M., Bandiera, T., Fogliatto, G., and Bertrand, J. A. (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49, 6813-6825
40. Donella-Deana, A., Marin, O., Cesaro, L., Gunby, R. H., Ferrarese, A., Coluccia, A. M., Tartari, C. J., Mologni, L., Scapozza, L., Gambacorti- Passerini, C., and Pinna, L. A. (2005) Unique substrate specificity of anaplastic lymphoma kinase (ALK). Development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 8533-8542
41. Tartari, C. J., Gunby, R. H., Coluccia, A. M., Sottocornola, R., Cimbro, B., Scapozza, L., Donella-Deana, A., Pinna, L. A., and Gambacorti-Passerini, C. (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J. Biol. Chem. 283, 3743-3750
42. Hubbard, S. R. (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.EMBO J. 16, 5572-5581
43. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754
44. Liu, Y., and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364
45. Bryan, M. C., Whittington, D. A., Doherty, E. M., Falsey, J. R., Cheng, A. C., Emkey, R., Brake, R. L., and Lewis, R. T. (2012) Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors. J. Med. Chem. 55, 1698-1705
46. Dong, A., Xu, X., Edwards, A. M., Midwest Center for Structural Genomics, Structural Genomics Consordium, Chang, C., Chruszcz, M., Cuff, M., Cymborowski, M., Di Leo, R., Egorova, O., Evdokimova, E., Filippova, E., Gu, J., Guthrie, J., Ignatchenko, A., Joachimiak, A., Klostermann, N., Kim, Y., Korniyenko, Y., Minor, W., Que, Q., Savchenko, A., Skarina, T., Tan, K., Yakunin, A., Yee, A., Yim, V., Zhang, R., Zheng, H., Akutsu, M., Arrowsmith, C., Avvakumov, G. V., Bochkarev, A., Dahlgren, L. G., Dhe-Paganon, S., Dimov, S., Dombrovski, L., Finerty, P., Jr., Flodin, S., Flores, A., Gräslund, S., Hammerström, M., Herman, M. D., Hong, B. S., Hui, R., Johansson, I., Liu, Y., Nilsson, M., Nedyalkova, L., Nordlund, P., Nyman, T., Min, J., Ouyang, H., Park, H. W., Qi, C., Rabeh, W., Shen, L., Shen, Y., Sukumard, D., Tempel, W., Tong, Y., Tresagues, L., Vedadi, M., Walker, J. R., Weigelt, J., Welin, M., Wu, H., Xiao, T., Zeng, H., and Zhu, H. (2007) In situ proteolysis for protein crystallization and structure determination. Nat. Methods 4, 1019-1021
47. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326
48. Navaza, J. (1994) AMoRe. An automated package for molecular replacement. Acta Crystallogr. A 50, 157-163
49. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240-255
50. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of COOT. Acta Crystallogr. D 66, 486-501
51. Drew, A. E., Al-Assaad, S., Yu, V., Andrews, P., Merkel, P., Szilvassy, S., Emkey, R., Lewis, R., and Brake, R. L. (2011) Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. J. Biomol. Screen 16, 164-173
52. Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., and Aoki, Y. (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679-690
53. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Active and inactive protein kinases. Structural basis for regulation. Cell 85, 149-158
54. Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., Peifer, M., Weiss, J., Lovly, C. M., Grütter, C., Rauh, D., Pao, W., and Thomas, R. K. (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 17, 7394-7401
55. Wood, A. C., Laudenslager, M., Haglund, E. A., Attiyeh, E. F., Pawel, B., Courtright, J., Plegaria, J., Christensen, J. G., Maris, J. M., and Mosse, Y. P. (2009) Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. J. Clin. Oncol. 27, 10008b
56. Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., Ishikawa, Y., Kimura, H., Mitsudomi, T., Tanio, Y., and Mano, H. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739
57. McTigue, M. A., Timofeevski, S. L., Liu, W., Deng, Y. L., Marrone, T., Cui, J., and Brooun, A. (2011)Structural and kinetic characterization of crizotinib with wild-type and mutant anaplastic lymphoma kinase. Cancer Res. 71, Abstr. 2327
58. Potashman, M. H., Bready, J., Coxon, A., DeMelfi, T. M., Jr., DiPietro, L., Doerr, N., Elbaum, D., Estrada, J., Gallant, P., Germain, J., Gu, Y., Harmange, J. C., Kaufman, S. A., Kendall, R., Kim, J. L., Kumar, G. N., Long, A. M., Neervannan, S., Patel, V. F., Polverino, A., Rose, P., Plas, S., Whittington, D., Zanon, R., and Zhao, H. (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem. 50, 4351-4373
59. Nolen, B., Taylor, S., and Ghosh, G. (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15, 661-675
60. Lewis, R. T., Bode, C. M., Choquette, D. M., Potashman, M., Romero, K., Stellwagen, J. C., Teffera, Y., Moore, E., Whittington, D. A., Chen, H., Epstein, L. F., Emkey, R., Andrews, P. S., Yu, V. L., Saffran, D. C., Xu, M., Drew, A., Merkel, P., Szilvassy, S., and Brake, R. L. (2012) The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J. Med. Chem. 55, 6523-6540
61. Munshi, S., Kornienko, M., Hall, D. L., Reid, J. C., Waxman, L., Stirdivant, S. M., Darke, P. L., and Kuo, L. C. (2002) Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J. Biol. Chem. 277, 38797-38802
62. Lietha, D., and Eck, M. J. (2008) Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 3, e3800
63. Westwood, I., Cheary, D. M., Baxter, J. E., Richards, M. W., van Montfort, R. L., Fry, A. M., and Bayliss, R. (2009) Insights into the conformational variability and regulation of human Nek2 kinase. J. Mol. Biol. 386, 476-485
64. Druker, B. J. (2004) Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30